First of a new breed of anticancer antibodies approved in Japan


The first in a new class of immune-oncology drugs has been approved for use in Japan. Ono pharmaceuticals’ Opdivo (nivolumab) has been approved for treating melanomas where surgery is impossible.

Nivolumab is part of a new wave of cancer therapies that encourage our immune systems to fight cancers or enhance their performance. It targets programmed cell death (PD1) receptors that are expressed on tumour cell surfaces to ward off detection by the immune system.

Ono developed the monoclonal antibody in conjunction with US biotech Medarex, which was acquired by Bristol-Myers Squib (BMS) in 2009. BMS is developing the drug outside of Japan, Korea and Taiwan.


Related Content

First biosimilar antibody drugs approved in Europe

11 September 2013 Business

news image

European commission gives final approval to generic infliximab copies

Business roundup

29 September 2011 Business

news image

Industry news, October 2011

Most Read

Lawrencium experiment could shake up periodic table

9 April 2015 Research

news image

Measurement of first ionisation energy confirms electronic configuration but opens up an important debate

Silicon chip spots dangerous pathogens in human blood

10 April 2015 Research

news image

Silicon wafer doped with silver nanoparticles can rapidly identify E. coli in blood

Most Commented

Women twice as likely to be hired for academic posts as men

17 April 2015 News and Analysis

news image

Experiment shows that faculty staff are more likely to pick women for job roles based on hypothetical CVs

Lawrencium experiment could shake up periodic table

9 April 2015 Research

news image

Measurement of first ionisation energy confirms electronic configuration but opens up an important debate